CTIX Stock Alert 11/01/2014 23:41:27 $CTIX The CEO of

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
CTIX Stock Alert 11/01/2014 23:41:27 $CTIX
The CEO of Polymedix made similar comments over 2 years ago:

Quote:
"PMX-30063, now referred to as brilacidin, is the first compound in the new cidin class of antibiotics," commented Nicholas Landekic, President and CEO of PolyMedix. "The cidins are unlike any other class of systemic antibiotic approved or in development. They imitate how our body's own immune system combats bacterial infections. Brilacidin, our lead clinical compound, kills bacteria that are resistant to other antibiotic classes, with a mechanism to which resistance is unlikely to develop. ---Polymedix PR June 12, 2012


It's 2 years later "and many people still don't fully grasp," but being a slow learner to this game will be costly.

http://www.globenewswire.com/news-release/201...30063.html


That's the first I've heard that on the board. I just re-read the Aug 7 PR and I didn't get a sense of disappointment or anything indicating suspicion of failure. Unless there are any errors found or procedural objections before data release, it sounds to me like P passed.
"What I see — and what I think many people still don’t fully grasp — is that Brilacidin is not just a potential blockbuster for the indication of ABSSSI, including infections caused by MRSA, but this trial provides proof-of-efficacy data for defensin-mimetics as a novel class of antimicrobials that may be used to treat a broad array of diseases and conditions with a very limited chance for drug resistance to develop." - Dr. James Alexander, COO of CTIX

Very pleased with the initial communication from the COO... sounds like a great addition to the team... good to know that Dr. Alexander can help run the show... especially since Leo could get arrested any day now for stealing those PolyMed assets right out from under the noses of big pharma...
A pass on partnership at this time may very well speak volumes as to how research and development, ongoing trials, and concluded trial results are being perceived by CTIX management. These guys know so much more than has been PR'd. The better the current state of affairs and prospects for approval of multi-billion dollar drugs the less urgency to jump at the first offer for financial security. I like your reasoning and thinking. And I love the potential list of trials within a year. Imagine the number of PR's coming from that many active trials.
Absolutely! As in "steal" a HUGE MAJORITY of that $7.3 billion market. Then on top of that add the B and K platforms. CTIX is going to be a MONSTER - the stock of the century. Thank you Patrick Cox for introducing me to CTIX!

Quote:
I would imagine if prurisol was approved and at this juncture, i have no reason to believe otherwise. Prurisol should be able to come in to the market and steal a huge share of the market if it does indeed act as a cure vice a maintenance treatment? - jok

Prurisol is not a "biologic" and it won't be cheap.
Celgene is keeping a very close eye on this drug and may partner up with CTIX.

Leo knows the VP of Celgene very well

Celgene has 8 billion is cash and has the infrastructure to take this one all the way.

Celgene's psoriasis drug is performing poorly.
I would imagine if prurisol was approved and at this juncture, i have no reason to believe otherwise. Prurisol should be able to come in to the market and steal a huge share of the market if it does indeed act as a cure vice a maintenance treatment?
JOK,
I was doing some DD and was about to post these quotes. I just saw your last post covered this, but hated to waste the effort.

"Biologics are potent psoriasis treatments. They work well to treat moderate or severe psoriasis, says Mark Lebwohl, MD, chairman of the National Psoriasis Foundation Medical Board, and he says he prefers them over other psoriasis drugs.

But they also have two key drawbacks:

Biologic drugs are expensive. Depending on the drug and the dose, they can cost $10,000 to $30,000 a year.
Biologics suppress the immune system. That means they can increase the risk for infection.

Almost 7.5 million people in the U.S. have a form of psoriasis. Celebrities such as TV personality Kim Kardashian, singer LeAnn Rimes, and swimmer Dara Torres all have it."

http://www.webmd.com/skin-problems-and-treatm.../biologics


" Between 2000 and 2008, the average wholesale price of five popular psoriasis drugs increased at a rate nearly five times that of inflation, according to a study published earlier this year in the Archives of Dermatology. During that period, the price of a dose of Enbrel increased by nearly 50%, to about $208; a dose of Humira increased to $831"

http://www.health.com/health/condition-articl...22,00.html

And our 18.00 2015 price target will certainly fit that bill. Cellceutix patience required grasshopper.........................Leo is boss (adjective).
worldwide psoriasis market


http://www.prweb.com/releases/psoriasis_drugs...855734.htm
https://secure.marketwatch.com/story/cellceut...2014-08-08
Even, I agree with you both and still feel as I felt back when, that they already know the answer on P and probably have pictures locked away in a safe in a far away land. Tehe.

GO CTIX
Looks like someone missed yesterday's PR.

"I believe the safety profile of Kevetrin has been very well evaluated in the current trial and is reassuring when Kevetrin is used a single agent and potentially in combination with other therapy."

Notice that the word "potentially" is not used in front of "a single agent" but is used in front of "in combination". Insiders know a lot more facts than us outsiders. You should believe that.

Quote:
I believe that you should NOT expect any miracles from Kevetrin as a single agent. I hope that I am wrong about Kevetrin but I strongly suspect I am right on target based on all the FACTS current made public.


I'm not sure either, but Leo did say it was pretty much a given. That's all I really need.
That depends on the size of the study. But, this will be a fairly quick trial similar to Brilacidin with only a few months of follow on data for each patient. It could range between 300 and 1000 patients, but it would be recruitment reaching out to other clinics, and not be ITT cases unless they were going for uncontrolled cases which would qualify for accelerated review under unmet need.
The primary endpoint, conversion to Abacavir, was met and the company has completed the design of a Phase 2/3a trial. That was announced, or so I thought. They will meet soon with the FDA for guidance, if they have not already met.

Listen to 6:00 to 6:20:
http://cellceutix.com/wp-content/uploads/2014...rt-2-1.mp3
I'm praying that the reason the official data has not been disclosed as of yet, is that CTIX wants to tell us that not only was the P1 endpoints realized, but we have a green light for a P2/3 trial.
Your post brings back memories of how excited we all were for Prurisol before the Polymedix heist.

Question,... if they are able to start the Prurisol trial sometime in Q1 of 2015,... in your opinion,.. would there be any possibility we would have Top-Line data before the end of 2015,...?

Thanks!
Quote:
I think the medium dose would have produced the same results but it seems some of the patients didn't come back for evaluation.

Exactly. They didn't come back because either they were cured or they died. If they had died the PI would have followed up with that in the Phase 2a report. So, we can assume they were cured which would bring the results for the medium dose to ~95.
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 10/30/2014 4:31:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/24/2014 6:04:28 AM
ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK "InvestorsHub NewsWire" - 10/14/2014 6:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/24/2014 3:48:22 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/15/2014 1:50:04 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 9/4/2014 4:14:23 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/2/2014 6:29:26 AM
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant "Marketwired" - 6/23/2014 7:00:00 AM
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort "Marketwired" - 6/16/2014 7:00:00 AM
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol "Marketwired" - 6/2/2014 7:00:00 AM
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities "Marketwired" - 5/27/2014 7:00:00 AM
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market "Marketwired" - 5/19/2014 7:00:00 AM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 5/16/2014 11:57:54 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/12/2014 10:12:29 AM
Cellceutix Confident in Its Formidable Antibiotic Arsenal "Marketwired" - 5/12/2014 7:00:00 AM
Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis "Marketwired" - 5/5/2014 9:53:20 AM
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae "Marketwired" - 4/14/2014 6:30:00 AM
Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid "Marketwired" - 4/1/2014 8:00:00 AM
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI "Marketwired" - 3/31/2014 9:25:00 AM
Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis "Marketwired" - 3/25/2014 6:00:00 AM
Cellceutix to Initiate Psoriasis Clinical Trial "Marketwired" - 3/21/2014 6:00:00 AM
Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors "Marketwired" - 3/19/2014 8:40:37 AM
Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial "Marketwired" - 3/10/2014 6:00:00 AM
Cellceutix Expands to Gram-Negative Bacterial Infections "Marketwired" - 3/5/2014 6:00:00 AM
Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial "Marketwired" - 2/26/2014 6:00:00 AM
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 55

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 49

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 618

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 52

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating the Legacy of the Kashi Fair: A Cultural Journey

Updated Category News Views 387

The Kashi Fair: A Living Tribute to the Silk Road The Kashi Fair, also known as the Kashi-Central and South Asia Commodity Fair, has become an essential trade event, connecting cultures and economies while celebrating the essence of the historic Silk Road. For Pakistani businessman Muhammad Abbas, the Managing Director of Pakistan Northern Gems, this annual event in Kashi...

Continue Reading
Global Forum Focuses on Sustainable Future and Cooperation

Updated Category News Views 260

Global Leaders Gather to Discuss a Sustainable Future Under the theme "Collective Action for One Future", a significant forum took place in a vibrant city, bringing together over 130 leaders from various nations. This event marked the ninth edition of an esteemed international gathering focused on transformative issues affecting the worldwide landscape. For the first...

Continue Reading
Blue Onion Secures $10 Million to Enhance Financial Data Management

Updated Category News Views 294

Blue Onion Secures $10 Million Series A Funding In a significant advancement for financial data management, Blue Onion has successfully secured $10 million in a Series A funding round, led by Viola FinTech. This strategic investment aims to broaden Blue Onion's capabilities in delivering accurate and fully reconciled transaction-level data that CFOs can trust. With this...

Continue Reading
Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Updated Category News Views 120

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...

Continue Reading
Investing in Houlihan Lokey: A Decade of Growth Insights

Updated Category News Views 176

Understanding the Investment Journey with Houlihan Lokey Houlihan Lokey (NYSE: HLI) has demonstrated remarkable performance over the past decade. This investment bank has outshined market averages, yielding an impressive annualized return of 22.61%. As of now, Houlihan Lokey boasts a significant market capitalization of $12.57 billion, showcasing its robust standing in...

Continue Reading